45 results about "Excess weight" patented technology

The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.

The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.

The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.

Use of at least one strain of a microorganism and / or a metabolite thereof in the manufacture of a support for administration to a subject for modulating satiety signalling, wherein the support is a pharmaceutically acceptable support or a food product. Suitably, the at least one strain of a microorganism and / or a metabolite thereof may be administered to the subject for the treatment and / or prevention of excess weight and / or a disease caused by excess weight. Likewise, the at least one strain of a microorganism and / or a metabolite thereof is administered to the subject for the treatment and / or prevention of obesity and / or a caused by obesity. Preferably, the microorganism is a probiotic microorganism. Suitably the microorganism may be a lactic acid bacterium. Li one embodiment the microorganism is a strain of Lactobacillus spp. and / or Bifidobacterium spp., for example a strain of Lactobacillus acidophilus, L. curvatus, L. salivarius and / or B. lactis.

The invention relates to the use as a drug or medical nutritional product in humans to treat a pathological dysbiosis and / or to prevent or treat at least one derived metabolic disease chosen from among excess weight with comorbidity, obesity, diabetes, heart and vascular diseases, atherosclerosis, degenerative bone disease, neurodegenerative disease, metabolism-related cancers, autoimmune diseases, steatosis, metabolic steatohepatitis, and chronic inflammatory diseases of the intestine, by increasing the Christensenella bacterial genus in the intestine, of a composition comprising a mixture of active ingredients consisting of at least:a whey hydrolysate with a molecular weight comprised between 200 and 10,000 Daltons,a whey isolate and / or a concentrate, andcalcium caseinate.

Gastric stimulation systems and methods are provided for treating a patient, particularly by modifying behavior of the patient leading to excess weight loss. In some embodiments, such weight loss is achieved with a combination approach which includes two or more of the following: acute screening of the potential patients, gastric stimulation, induction of symptoms or specific behaviors and integration of patient management data into the treatment plan. Gastric stimulation is provided to portions of the gastrointestinal tract, particularly the stomach, with the use of at least one electrode. A variety of gastric stimulation systems may be used, including stimulators that are endoscopically placed, laparoscopically placed or placed by modified or combination methods.